Compare Abeona Therapeutics Inc (ABEO) vs Elastic NV (ESTC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Elastic NV — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Elastic NV trades at $59.61 (market cap $6.18B). The key difference: Elastic NV is far larger — about 16.6× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Elastic NV nearer its low. Which is the better fit depends on your goals.
| ABEO | ESTC | |
|---|---|---|
Market Cap | $373.32M | $6.18B |
Sector | Health | Technology |
52-Week High | $7.23 | $94.47 |
52-Week Low | $4.17 | $43.30 |
Enterprise Value | $228.22M | $5.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Elastic (ESTC) trades at $58.54, up 0.86% with neutral technical signals. The company shows strong profitability metrics including 76% gross margins and 21% net income margin projected for 2026, though 2025 results showed a net loss. Recent earnings beats and positive analyst sentiment (67% buy ratings) support the stock, with a $72.80 consensus price target representing 24% upside potential.
ESTC presents a growth opportunity with improving financials and market leadership in search AI, though risks include ongoing legal investigations and competitive pressures. The stock's current valuation appears reasonable relative to growth prospects, with technical indicators suggesting consolidation near key support at $57.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →
